Teleflex
Wayne, Pennsylvania, United States · Biotechnology, Health Care, Medical
Teleflex is a global provider of medical technologies designed to improve the health and quality of people's lives. The company specializes in vascular intervention, surgical instruments, and anesthesia technologies. Teleflex is committed to investing in innovative solutions to enhance patient care and outcomes. They operate in numerous markets worldwide.
Key facts
- Headquarters
- Wayne, Pennsylvania, United States
- Employees
- 14,000
- Industries
- Biotechnology, Health Care, Medical
- Status
- Public (TFX)
- Website
- teleflex.com
- Company page
Recent activity at Teleflex
- : SEC 8-K (5.02): On September 8, 2026, Teleflex Incorporated's Board of Directors increased its size from eight to nine members and elected Sean M. Salmon to fill the newly created vacancy. Mr. Salmon, age 61, is the founder of Zamboni Holdings, LLC, established in December 2025, and previously worked for 21 years at Medtronic plc. His election is significant as he will also serve on the Growth and Operating Committee of the Board, potentially impacting the company's strategic direction and decisions. This change reflects the company’s intent to enhance its governance and operational expertise.
- : SEC 8-K (8.01): On August 7, 2026, Teleflex Incorporated announced the entry into an accelerated share repurchase program (ASR Transaction) with Truist Bank, aiming to repurchase $250 million worth of its common stock as part of a larger $1 billion share repurchase initiative. The ASR Transaction entails an initial delivery of the common stock valued at 80% of the Repurchase Price, with payments scheduled for August 10, 2026. The execution of this transaction will be funded by the proceeds from the sale of the Company’s Original Equipment Manufacturing and Development Services business, indicating a strategic shift in capital deployment. This program is set to terminate in the fourth quarter of 2026 but could conclude earlier if the counterparty opts to do so.
- : SEC 8-K (7.01): Teleflex Incorporated is providing a Regulation FD Disclosure related to a conference call scheduled for August 6, 2026, to discuss its financial results for the quarter ended June 30, 2026. During this call, the Company intends to reference a slide presentation, which will be available on its website prior to the call. The slide presentation is attached as Exhibit 99.2 to this filing. This event is significant as it pertains to the Company’s earnings disclosure and transparency with investors.
- : SEC 8-K (2.01): On August 3, 2026, Teleflex Incorporated completed the sale of its Original Equipment Manufacturing and Development Services business to Lotus US Bidco Inc. for a purchase price of $1.5 billion in cash. This transaction was carried out pursuant to the Equity Purchase Agreement dated December 9, 2025. In addition to the sale, multiple ancillary agreements were established, including a transition services agreement and a long-term supply agreement, which will facilitate operations for both parties. The completion of this acquisition marks a significant strategic shift for Teleflex, allowing it to focus on core business areas while providing the OEM Purchaser with established operational capabilities in the OEM market.
- : SEC 8-K (1.01): On June 15, 2026, Teleflex Incorporated entered into a material definitive agreement by issuing $500,000,000 aggregate principal amount of 5.875% senior notes due January 2032. The notes will pay interest semi-annually beginning January 15, 2027, and are secured by the company and its guarantors' existing and future senior obligations. The agreement allows for optional redemption prior to January 15, 2029, under specified conditions. This financing is strategically significant as it impacts the company’s capital structure and liquidity moving forward.
- : Teleflex Appoints Stuart A. Randle as Interim CEO with Special Award
- : SEC 8-K (5.02): On June 8, 2026, Teleflex Incorporated's Board of Directors approved a special restricted stock unit award worth $600,000 to Stuart A. Randle in recognition of his contributions as Interim President and Chief Executive Officer. The award acknowledges Mr. Randle's extended service in this role and his impact on operational, governance, and investor relations matters, as well as his involvement in the search for a permanent CEO. The grant date for the award is June 8, 2026, with a vesting schedule that will occur on the earlier of June 8, 2027, or at the Company's 2027 annual meeting of stockholders. This decision reflects the Board's appreciation for Mr. Randle's continued leadership during a critical transition period for the Company.
- : SEC 8-K (5.02): On June 8, 2026, Teleflex Incorporated's Board of Directors approved a special restricted stock unit award valued at $600,000 to Stuart A. Randle in recognition of his significant contributions as Interim President and Chief Executive Officer. This award acknowledges Mr. Randle's extended service and his role in operational, governance, and investor relations matters while heading the search for a permanent CEO. The decision was made by the independent members of the Board upon the recommendation of the Compensation Committee, reflecting the strategic importance of his leadership during this transitional period.
- : SEC 8-K (8.01): On June 1, 2026, Teleflex Incorporated announced the pricing of its private offering of $500.0 million aggregate principal amount of 5.875% Senior Notes due 2032. The company plans to utilize the proceeds, along with cash on hand, to redeem all outstanding 4.625% Senior Notes due 2027. The offering is expected to close around June 15, 2026, contingent upon customary closing conditions and is being made only to qualified institutional buyers in accordance with relevant securities regulations. This strategic move signifies Teleflex's efforts to restructure its debt obligations and optimize its capital structure.
- : SEC 8-K (8.01): On June 1, 2026, Teleflex Incorporated announced its intention to offer $500.0 million aggregate principal amount of Senior Notes due 2032. The company plans to use the net proceeds from this offering, along with available cash, to redeem all outstanding 4.625% Senior Notes due 2027. The offering is targeted towards qualified institutional buyers under Rule 144A and certain non-U.S. persons outside the United States according to Regulation S of the Securities Act. This preliminary offering memorandum includes key financial metrics like unaudited Adjusted EBITDA and is provided for illustrative purposes only. The transaction is significant as it represents a strategic move to manage debt maturity and potentially reduce interest costs.
Leadership
- Stuart A. Randle, Chief Executive Officer
- Jason Weidman, Chief Executive Officer
- Ainsley Avery Royals, Human Resources Director
- Tim Duffy, Vice President
Verified email and direct lines for Teleflex’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Teleflex files 6 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Teleflex in the news
- Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology - Business Wire (Sep 29, 2026)
- Teleflex Announces Second Quarter 2026 Earnings Conference Call Information - Yahoo Finance (Jul 23, 2026)
- Teleflex Publishes 2025 Global Impact Report - Business Wire (Jul 07, 2026)
- Teleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion - Business Wire (Aug 03, 2026)
- Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors - Business Wire (Sep 08, 2026)
- Teleflex Reports First Quarter Financial Results and Full Year 2026 Outlook - Business Wire (May 07, 2026)
Companies similar to Teleflex
- Edwards Lifesciences · Biotechnology, Health Care, Medical, Medical Device
- Zimmer · Biotechnology, Health Care, Medical, Medical Device
- Intuitive Surgical · Biotechnology, Health Care, Medical, Medical Device
- Solventum · Biotechnology, Health Care, Medical, Medical Device
- Terumo Blood and Cell Technologies · Biotechnology, Health Care, Medical, Medical Device
About Teleflex: questions and answers
What does Teleflex do?
Teleflex is a global provider of medical technologies designed to improve the health and quality of people's lives. The company specializes in vascular intervention, surgical instruments, and anesthesia technologies. Teleflex is committed to investing in innovative solutions to enhance patient care and outcomes. They operate in numerous markets worldwide.
Where is Teleflex headquartered?
Teleflex is headquartered in Wayne, Pennsylvania, United States.
How many employees does Teleflex have?
Teleflex has about 14,000 employees.
Who leads Teleflex?
Stuart A. Randle is a Chief Executive Officer at Teleflex.
What is the latest news on Teleflex?
On Sep 08, 2026, SEC 8-K (5.02): On September 8, 2026, Teleflex Incorporated's Board of Directors increased its size from eight to nine members and elected Sean M. Salmon to fill the newly created vacancy. Mr. Salmon, age 61, is the founder of Zamboni Holdings, LLC, established in December 2025, and previously worke
Is Teleflex a public company?
Yes. Teleflex is publicly traded under the ticker TFX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy